This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
B cell lymphoma (BCL)	B cell CLL lymphoma 6 (BCL6); heat shock protein 90 (Hsp90); histone deacetylase (HDAC)	<i>In vitro</i> and mouse studies suggest that HDAC or Hsp90 inhibitors could be used in combination with BCL6 inhibitors to treat diffuse large BCL. In diffuse BCL cells dependent on BCL6, a peptide inhibitor of the target plus either an HDAC inhibitor or an Hsp90 inhibitor increased apoptosis compared with any treatment alone. The combination also suppressed tumors in lymphoma xenograft mice better than any treatment alone or vehicle control. Next steps could include testing the combination in additional animal models. At least four companies have HDAC inhibitors in clinical testing to treat BCL.	Patent and licensing status unavailable	Cerchiatti, L.C. <i>et al. J. Clin. Invest.</i> ; published online Nov. 1, 2010; doi:10.1172/JCI42869 Contact: Ari Melnick, Weill Cornell Medical College, New York, N.Y. e-mail: amm2014@med.cornell.edu
<i>SciBX</i> 3(45); doi:10.1038/scibx.2010.1347 Published online Nov. 18, 2010				